The tweet was deleted by the author.
But we saved everything 🙂.
UroGen Pharma states that Jason, with experience in healthcare, pharmaceutical, and corporate law, plays a key role in guiding the company through regulatory changes.
UroGen Pharma says Jason fosters a culture of integrity and accountability in the organization. The company invites readers to learn more about its leadership.
View post on X Loading...
URGN is trading at $34.88, firmly above its 20-day ($30.45), 50-day ($28.17), and 200-day ($22.48) SMA levels, indicating persistent bullish momentum across short, medium, and long-term trends. The Ichimoku Kijun sits at $31.04, positioning it as immediate support beneath the current price. Near-term support is found at the Ichimoku Kijun ($31.04), followed by key support at the 50-day SMA ($28.17). On the upside, near-term resistance is at the 5-day SMA ($34.90), with key resistance at the recent 52-week high ($36.08).
MACD and ADX on D1 both show firm buy signals, confirming strong underlying momentum. RSI (70.28, D1) and CCI (94.93, D1) are near overbought territory, while Stoch RSI is neutral, exposing a mild divergence. BBP on D1 is in an overbought state, indicating buyers remain in control, and the Awesome Oscillator also supports the positive trend. URGN is trading at $34.88, up from $34.54 a week ago, reflecting a 1.13% gain. The price currently sits in the middle of the weekly range, with weekly volatility at 6.75%. The weekly tone suggests consolidation near recent highs.
For the coming week, the expected price corridor is $33.25 to $36.00, keeping the move within a realistic band around the current price and retracing towards the 52-week high of $36.08. There is a very high probability (more than 80%) of continued upside, as both W1 and D1 signals for the major momentum indicators (RSI-W1, ADX-W1, MACD-W1, and MA-50-W1) are bullish. The base case assumes consolidation between $33.25 and $36.00. A bullish scenario would see a breakout above $36.00 toward fresh yearly highs, while a bearish scenario emerges if the price falls below $31.00, exposing further downside toward the 50-day SMA. URGN remains in the upper half of its annual range, showing robust relative outperformance year-to-date.
Earlier, analysts noted that UroGen Pharma exhibited medium- and long-term bullish momentum even as near-term resistance tempered immediate upside. The current analysis provides an updated perspective on prevailing risks, highlighting a key support level that investors should monitor as market sentiment evolves.